Fairfield Market Research
Insomnia Market

Insomnia Market

Global Industry Analysis (2018 - 2021) - Growth Trends and Market Forecast (2022 - 2029)

Published Date: Upcoming | Format:

Industry: Pharmaceuticals & Biotechnology | Author Name: Sayali


Request TOC More Information

Increasing Work Stress Due to a Highly Competitive Lifestyle of Individuals will Increase the Insomnia Condition

Irregular work shifts have an impact on the quality and cycle of sleep. According to WHO, 264 million people suffer from depression, which is mainly caused by work-related stress. Such a large pool of patients is likely to experience insomnia, which is anticipated to drive demand for effective insomnia treatment, thereby fuelling the growth of insomnia market. Moreover, the COVID-19 pandemic caused employment losses for many individuals as industries failed to function correctly, contributing to an increase in stress among people.  According to ILO, in 2020, there were record global job losses of 114 million jobs compared to 2019. This has caused an increase in the stress level of the individuals during the pandemic period, resulting in the growth of the insomnia market.

Orexin Antagonist Segment is Anticipated to Dominate Insomnia Treatment Type due to Minimal Side Effects

Orexin Antagonist segment is expected to grow within the forecast period. Suvorexant (MK-4305, Merck) is the first in a new class of insomnia medications known as ORAs (orexin receptor antagonists). By suppressing the arousal system's wakefulness-promoting orexin neurons, the aid of the tablets in the natural shift from restlessness to sleep. Suvorexant promotes the onset and maintenance of sleep. This separate option has favourable permissibility and a limited side-effect profile. The mechanism of action of suvorexant differs from that of benzodiazepines and non-benzodiazepines since it has no effect on Gamma-aminobutyric acid (GABA). It deactivates wakefulness rather than encouraging sleep. For instance, the US Food and Medication Administration (FDA) approved the new drug application for Easai's in-house discovered and developed orexin receptor antagonist DAYVIGOTM in December 2019. (lemborexant). DAYVIGO was licensed for the treatment of adult insomnia characterised by sleep onset and/or sleep maintenance issues. Due to developments in this class of medications, the segment is likely to grow steadily over the forecast period.

North America Dominant Insomnia Market with the Largest Patient Pool

The insomnia market has been dominated by North America. Over the projected period, the insomnia market here will be driven by the growing need for sleep disorder treatment in the United States and Canada, as well as the rising prevalence of sleep disorders. Additionally, the presence of sleep-related support groups in the country is a major driving factor for the industry. The Canadian Sleep Society is one such national organization dedicated to improving sleep for all Canadians by funding research, promoting high-quality clinical care, educating professionals and the public, and advocating for sleep and sleep disorders medicine. Furthermore, the presence of leading market competitors, as well as the R&D of new pharmaceuticals and product releases, are projected to drive the expansion of insomnia market under consideration.

The United States dominated North America due to the presence of the most sleep-deprived people and the usage of patented medications for therapy. Factors like adverse effects from certain OTC and prescription medications, arthritis, and excessive use of media devices before sleep are increasing the number of people suffering from insomnia, improving the prospects of the regional insomnia market. According to Cleveland Clinic, approximately 70 million American citizens suffer from insomnia out of which 50 percent are adults and 10-15% are children. Moreover, the increase in psychological circumstances and the steady increase in noise levels in the areas due to continuous infrastructure development will drive the insomnia treatment market throughout the projection period.

Asia-Pacific will continue to be a profitable region for the growth of the insomnia industry. The market expansion in the region may be highly ascribed to the increased stress level of the working population combined with shift-work-related sleep disorders. Governments in the region are always working to improve their healthcare systems and provide advantageous reimbursement policies, which may have an impact on the regional insomnia market. Over the next few years, developing countries such as China and India are likely to see an increase in demand for healthcare facilities and sleep aids. This would eventually open a slew of chances for top manufacturers looking to grow into these regional markets and gain a larger portion of the market. Japan is projected to dominate in Asia-Pacific due to technical improvements to offer unique treatment solutions for specific conditions. As per the survey carried out in Japan by a reputed organization, 49.3 percent of 10,000 participants in the survey were suffering from Insomnia which may indicate that around 50 percent of the Japanese populace is suffering from Insomnia. This factor is likely to drive regional growth in the coming years.

Global Insomnia Market: Competitive Landscape

Sector participants are presenting new products and developing collaborations, alliances, and partnership agreements. For instance, in February 2021, Eisai Limited, Eisai Inc.'s Canadian affiliate, acquired Canadian approval for its new non-sedative prescription drug, DAYVIGO (lemborexant). DAYVIGO, which is available in 5 mg and 10 mg doses, is recommended for the treatment of insomnia, which is characterized by difficulties with sleep start and/or sleep maintenance. For instance, in January 2021, Royalty Pharma plc and Minerva Neurosciences Inc. reached an agreement in which Royalty Pharma will buy Minerva's royalty stake in suvorexant. Seltorexant, a selective orexin 2 receptor antagonist, is now in Phase 3 development for the treatment of the major depressive disorder (MDD) symptoms associated with sleeplessness.

Few of the players in the Insomnia Market include Ernix Therapeutics Holdings, Inc., Paratek Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, Merck & Co Company, and Mylan N.V.

Global Insomnia Market is Segmented as Below:

By Treatment Type

  • Benzodiazepines
  • Nonbenzodiazepines
  • Antidepressants
  • Orexin Antagonist
  • Melatonin Antagonist
  • Devices
  • Other Treatment Types

By Sales Channel

  • Hospital Pharmacies
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • South Korea
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Key Elements Included In The Study: Global Insomnia Market

  • Insomnia Market by Product/Technology/Grade, Application/End-user, and Region
  • Executive Summary (Opportunity Analysis and Key Trends)
  • Historical Market Size and Estimates, Value, 2018 - 2021
  • Market Value at Regional and Country Level, 2022 - 2029
  • Market Dynamics and Economic Overview
  • Market Size in Value, Growth Rates, and Forecast Figures, 2022 - 2029
  • Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
  • Regional and Product/Grade/Application/End-user Price Trends Analysis
  • Value Chain and Five Force’s Analysis
  • Regional/Sub-region/Country Market Size and Trend Analysis
  • Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

  • The report will be prepared in a PPT format and will be delivered in a PDF format.
  • Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.
  • If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.
  • If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.
  • If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.

Disclaimer:

  • The segmentation/company profiles/countries depicted above may vary in the actual report.

Request Table of Contents

Our Research Methodology

Under uncertainty, traditional approaches to strategic planning can be downright dangerous. True ambiguity is no basis to forecast the future – degree of risk, the magnitude of circumstances, conditions and consequences are not known or unpredictable. To avoid dangerous binary views of uncertainty; strategic posture, moves and actions through market research is the best bet.

Read more
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services